Introduction
============

Ovarian cancer (OVCA) is the fifth leading cause of cancer-related mortality among women in the United States and Western Europe, with the highest mortality rate of all gynecologic malignancies. Approximately 75% of patients with OVCA are diagnosed at an advanced stage (III/IV) with disseminated intraperitoneal metastases ([@b1-or-29-05-2011]). Although the majority of patients initially experience a complete clinical response to primary surgery followed by platinum/taxane-based chemotherapy, most patients eventually develop platinum/taxane-resistant persistent or recurrent disease. These patients have a poor prognosis. Despite cytoreductive surgery and aggressive chemotherapy, the majority of patients with OVCA succumb to the disease within 5 years ([@b2-or-29-05-2011]). These dismal statistics highlight the need for research into the cellular basis of platinum response, as well as the design of targeted therapeutic strategies.

The hepatocyte growth factor (HGF) signaling pathway may be a viable target for the development of directed therapeutic regimens for the treatment of OVCA. HGF is the only known ligand of the HGF receptor (c-Met), which is expressed in approximately 70% of OVCAs ([@b3-or-29-05-2011],[@b4-or-29-05-2011]). Overexpression of HGF and/or c-Met has been associated with poor clinical outcome in OVCA ([@b5-or-29-05-2011]--[@b7-or-29-05-2011]), whereas c-Met overexpression has further been associated with a chemo-resistant subset of ovarian clear-cell adenocarcinomas ([@b8-or-29-05-2011],[@b9-or-29-05-2011]). The targeted inhibition of c-Met has been shown to reduce c-Met expression, block OVCA cell proliferation, and reduce tumor burden in pre-clinical mouse models ([@b10-or-29-05-2011]--[@b12-or-29-05-2011]).

In this study, we analyzed the expression of the HGF receptor, c-Met, in primary OVCA and OVCA cell lines, and tested the activity of the HGF/c-Met signaling inhibitor, MK8033, alone and in combination with standard of care therapy (carboplatin plus paclitaxel) in a panel of OVCA cells. We then identified the genes associated with sensitivity to MK8033 plus carboplatin-paclitaxel and used the principal component analysis (PCA) to define a gene expression signature of OVCA cell response. Finally, this PCA response signature was tested in an independent survival dataset of primary OVCA for which response to chemotherapy and overall survival were known.

Materials and methods
=====================

Cell culture
------------

OVCA cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA) (CAOV3, OV90, OVCAR3 and SKOV3); from the European Collection of Cell Cultures (Salisbury, England) (A2780CP and A2780S); from Kyoto University (Japan) (CHI, CHIcisR, M41, M41CSR, Tyknu and TyknuCisR); or were kind gifts from Dr Patricia Kruk, Department of Pathology, College of Medicine, University of South Florida, Tampa, FL, and Professor Susan Murphy, Department of OBGYN/Division of Gynecologic Oncology, Duke University, Durham, NC, USA (A2008, C13, CAOV2, HeyA8, IGR-OV1, IMCC3, IMCC5, MCAS, OV2008, OVCA420, OVCA429, OVCA432, OVCA433, FUOV1, PEO1, PEO4, SK-OV-6, T8, TOV-112D, TOV-21-G, Dov13, BG1, Ovary1847, OVCAR10, OVCAR8, OVCAR5, OVCAR4, OVCAR2 and SK-OV-4). Cell lines were maintained in RPMI-1640 (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Fisher Scientific, Pittsburg, PA, USA), 1% sodium pyruvate, 1% penicillin/streptomycin (Cellgro, Manassas, VA, USA), and 1% nonessential amino acids (HyClone, Hudson, NH, USA). Mycoplasma testing was performed every 6 months in accordance with the manufacturer\'s protocol (Lonza, Rockland, ME, USA).

Staining and scoring of c-Met expression in OVCA
------------------------------------------------

Slides were stained using a Ventana Discovery XT automated system as per the manufacturer\'s protocol with proprietary reagents (Ventana Medical Systems, Tucson, AZ, USA). Briefly, slides were deparaffinized on the automated system with EZ Prep solution (Ventana). The heat-induced antigen retrieval method was used in Cell Conditioning 1 (Ventana). The mouse monoclonal antibody that reacts to c-Met (\#18-7366; Invitrogen) was used at a 1:2,000 concentration in PSS antibody diluent (Ventana) and incubated for 60 min. The Ventana OmniMap anti-mouse secondary antibody was used for 16 min. The detection system used was the Ventana ChromoMap kit, and slides were counterstained with hematoxylin. Slides were then dehydrated and coverslipped as per normal laboratory protocol. The c-Met expression score was defined as the product of intensity and cellularity, where an intensity of 1 was weak; 2, moderate; 3, strong, and a cellularity of 1 ≤33%, 2 =34--65% and 3 ≥66%.

RNA extraction and microarray expression analysis
-------------------------------------------------

RNA extraction and microarray expression analyses were performed as previously described ([@b13-or-29-05-2011]). Briefly, RNA was extracted using the RNeasy kit following the manufacturer\'s recommendations (Qiagen, Valencia, CA, USA). Quality of the RNA was measured using an Agilent 2100 Bioanalyzer. The targets for Affymetrix DNA microarray analysis were prepared according to the manufacturer\'s instructions. For OVCA cell lines (n=41), targets were hybridized to customized Human Affymetrix HuRSTA gene chips (HuRSTA-2a520709) \[GEO accession number GSE34615 ([@b14-or-29-05-2011])\].

Statistical analyses
--------------------

Expression data were subjected to background correction and normalization using the Robust Multichip Average algorithm in the Affymetrix Expression Console (<http://www.affymetrix.com/products/software/specific/expression_console_software.affx>). Pearson\'s correlation test was performed on individual gene expression and IC~50~ values. Probe sets with P\<0.001 were considered to have significant correlations with IC~50~ values.

Cell viability assays
---------------------

For cells cultured in the presence of cisplatin, resistance was quantified using MTT proliferation assay, in accordance with manufacturer\'s instructions (Promega, Madison, WI, USA). Cells (5,000/well) were seeded in 96-well plates, allowed to adhere, and incubated with increasing doses of cisplatin for 48 h at 37°C. Following drug incubation, plates were read at 570 nm using a SpectraMax 190 microplate reader (Molecular Devices, USA). For drug combination experiments, CellTiter-Blue cell viability assays were performed using 384-well plates and an automated pipetting station. Briefly, for these assays, 1.2×10^3^ cells (24-μl volume) were plated in each well and allowed to adhere overnight at 37°C and 5% CO~2~. Drug dilutions were then added using the same pipetting station, and the plate was incubated for 72 h. Following drug incubation, fluorescence was measured using a Synergy 4 microplate reader (Bio-Tek Instruments, Inc.). The fluorescence data were transferred to a spreadsheet program to calculate the percent viability relative to untreated cells. Experiments were repeated a minimum of three times.

Synergism analyses
------------------

Drug combination experiments were analyzed for synergistic, additive, or antagonistic effects using the combination index method developed by Chou and Talalay. For the application of this method, the drug concentration dilutions of the drugs were used at fixed dose ratios based on the IC~50~ values of each drug obtained from preliminary experiments (e.g., 50:1, 2:5, 1:250). Briefly, the dose-effect curve for each drug alone is determined based on experimental observations using the median-effect principle and is compared to the effect achieved with a combination of the two drugs to derive a combination index value. This method involves plotting dose-effect curves, for each agent and their combination, using the following median-effect equation: fa/fu = (D/Dm)m, where D is the dose of the drug, Dm is the dose required for a 50% effect (equivalent to IC~50~), fa and fu are the affected and unaffected fractions, respectively (fa=1-fu), and m is the exponent signifying the sigmoidicity of the dose-effect curve. The computer software program XLfit was used to calculate the values of Dm and m. The combination index values used for the analysis of the drug combinations were determined by the isobologram equation for mutually nonexclusive drugs that have different modes of action: combination index = (D)1/(Dx)1 + (D)2/(Dx)2 + (D)1(D)2/(Dx)1(Dx)2, where (Dx)1 and (Dx)2 in the denominators are the doses (or concentrations) for D1 (drug 1) and D2 (drug 2) alone that gives x% inhibition, whereas (D)1 and (D)2 in the numerators are the doses of drugs 1 and 2 in combination that also inhibited x% (i.e., isoeffective). Combination indices \<1, equal to 1, and \>1 indicate synergism, additive effects and antagonism, respectively.

Building signatures
-------------------

The PCA methodology was used to derive a gene expression signature with a corresponding score. First, the data were reduced into a small set of uncorrelated principal components. This set of principal components was generated based on its ability to account for variation. The first principal component (1st PCA) is used to represent the overall variability in the data. The gene expression score is equal to ∑*w~i~x~i~*, a weighted average expression among the differentially expressed genes, where *x~i~* represents gene *i* expression level, *w~i~* is the corresponding weight (loading coefficient) with ∑*w^2^~i~* = 1, and the *w~i~* values maximize the variance of ∑*w~i~x~i~*. Directional signs of PCA scores are recognized to be arbitrary and can vary between software and the algorithm used to calculate the PCA model ([@b15-or-29-05-2011]); however, this does not affect the interpretation of the PCA model and can be easily solved by multiplying both scores and loadings by −1, a 180° rotation. Details of this methodology have been reported by our group previously ([@b13-or-29-05-2011]).

Associations with overall survival from OVCA
--------------------------------------------

PCA models were then explored for associations with overall survival from OVCA (using median PC1 score as the threshold to define high vs. low pathway score) using a dataset for which both gene expression and overall survival data were available, the publicly available Australian (Aus) Dataset (Affymetrix U133Plus GeneChips, n=218).

Results
=======

c-Met is significantly expressed in OVCA
----------------------------------------

Since overexpression of HGF has been associated with poor clinical outcome in OVCA ([@b5-or-29-05-2011]--[@b7-or-29-05-2011]), we evaluated the expression of c-Met, the only known HGF receptor, in OVCA cells and primary OVCA tumor samples. Pathological scoring of c-Met immunostains (cellularity × intensity) in 79 primary OVCA samples and 41 OVCA cell lines indicated the presence of c-Met expression in 92% (73/79) ([Table I](#tI-or-29-05-2011){ref-type="table"}) and 83% (34/41) ([Table II](#tII-or-29-05-2011){ref-type="table"}) of samples, respectively. c-Met expression in primary OVCA did not appear to be associated with stage, response to primary platinum therapy, or CA125 levels ([Table I](#tI-or-29-05-2011){ref-type="table"}).

Inhibition of HGF/c-Met signaling has in vitro anti-proliferative effects on OVCA cells and synergizes with combination carboplatin plus paclitaxel
---------------------------------------------------------------------------------------------------------------------------------------------------

To determine whether HGF signaling influenced OVCA cell line chemosensitivity, we evaluated the activity of MK8033, an inhibitor of HGF/c-Met signaling. MK8033 exhibited strong anti-proliferative effects against a panel of OVCA cell lines ([Fig. 1](#f1-or-29-05-2011){ref-type="fig"}). Furthermore, when combined in constant molar ratio of 1 with carboplatin plus paclitaxel (molar ratio of 20,000:1), MK8033 significantly lowered the carboplatin-paclitaxel IC~50~ in the majority of cell lines tested ([Fig. 1](#f1-or-29-05-2011){ref-type="fig"}). Combination index values calculated using the Chou-Talalay isobologram equation indicated synergistic activity between MK8033 and carboplatin-paclitaxel for almost all OVCA cell lines tested, as indicated by combination index values of \<0.7 ([Fig. 1](#f1-or-29-05-2011){ref-type="fig"}).

Molecular determinants of MK8033-carboplatin-paclitaxel sensitivity influence overall survival from OVCA
--------------------------------------------------------------------------------------------------------

Pearson\'s correlation test of IC~50~ values and Affymetrix HuRSTA genechip expression data identified 47 genes to be correlated with MK8033 plus carboplatin-paclitaxel sensitivity \[false discovery rate (FDR) of \<0.2\] ([Table III](#tIII-or-29-05-2011){ref-type="table"}). PCA modeling of these genes indicated that the expression signature was associated with overall survival from OVCA (AUS dataset, n=218, P=0.013) ([Fig. 2](#f2-or-29-05-2011){ref-type="fig"}).

Discussion
==========

HGF is a paracrine growth factor originally found to be associated with liver regeneration ([@b16-or-29-05-2011]--[@b18-or-29-05-2011]). HGF signaling orchestrates a multitude of biological functions during embryogenesis, including cellular migration, invasion, proliferation, angiogenesis, wound healing, and tissue repair ([@b19-or-29-05-2011]--[@b29-or-29-05-2011]), and has been further associated with the development or progression of several different types of cancer, including OVCA ([@b6-or-29-05-2011],[@b7-or-29-05-2011],[@b12-or-29-05-2011],[@b30-or-29-05-2011]--[@b45-or-29-05-2011]). In OVCA, increased levels of HGF or overexpression of the HGF receptor c-Met has been associated with poor clinical outcome ([@b5-or-29-05-2011]--[@b7-or-29-05-2011],[@b16-or-29-05-2011]--[@b18-or-29-05-2011]).

We found a near ubiquitous expression of c-Met in both primary OVCA and OVCA cell lines. To better understand the importance of HGF signaling in OVCA, we evaluated the activity of the novel inhibitor of HGF/c-Met signaling, MK8033, alone and in combination with carboplatin plus paclitaxel in a panel of OVCA cell lines (n=8). Although MK8033 showed anti-proliferative effects as a single agent, when used in a constant ratio to carboplatin-paclitaxel, the isobologram analysis indicated synergistic activity in the inhibition of OVCA cell proliferation. Pearson\'s correlation of cell line gene expression data and IC~50~ values identified the expression of 47 genes to be correlated with sensitivity to MK8033 plus carboplatin-paclitaxel. As shown by PCA modeling, genes correlated with MK8033 plus carboplatin-paclitaxel response were associated with overall survival from OVCA, suggesting that these genes may have a biological influence on OVCA response to therapy. Further analysis of the MK8033 plus carboplatin-paclitaxel response signature identified 6 of 47 genes to be significantly correlated with OVCA survival, including i) HFE (+ correlation, P=0.02); ii) UBQLN1 (+ correlation, P=0.04); iii) CLTCL1 (- correlation, P=0.04); iv) LPHN3 (- correlation, P=0.04); v) OSBPL6 (- correlation, P=0.03); and vi) SGK269 (- correlation, P=0.04).

The products of several of these genes have previously been implicated in the development and/or progression of cancer. For example, the product of the HFE gene, hemochromatosis protein, is involved in the regulation of iron absorption ([@b46-or-29-05-2011]). Mutations in HFE and deregulation of iron absorption have been linked to liver cirrhosis and colon cancer risk ([@b47-or-29-05-2011],[@b48-or-29-05-2011]). Ubiquilin 1, encoded by the UBQLN1 gene, has been shown to be associated with lung adenocarcinoma ([@b49-or-29-05-2011]) and may affect OVCA response to metallodrugs ([@b50-or-29-05-2011]). CLTCL1 encodes the heavy chain of clathrin, and the expression and/or activity of clathrin has been found to be associated with bladder cancer ([@b51-or-29-05-2011]), TRAIL-resistant breast cancer ([@b52-or-29-05-2011]), and uptake of some chemotherapeutic agents ([@b53-or-29-05-2011]). Furthermore, the oxysterol binding protein (OSBP)-related protein 6, encoded by the OSBPL6 gene, belongs to a family of proteins recently identified as receptors for several natural products, including cephalostatin-1, ritterazine B, schweinfurthin A and OSW-1 ([@b54-or-29-05-2011]).

In summary, we showed that targeted inhibition of HGF/c-Met signaling using the c-Met specific inhibitor, MK8033, worked synergistically with combinations of carboplatin plus paclitaxel to induce OVCA cell growth arrest. Furthermore, we demonstrated that genes associated with response to MK8033 plus carboplatin-paclitaxel may influence overall survival from OVCA, based on PCA modeling. The results of this study suggest that the inhibition of HGF/c-Met signaling may be a beneficial addition to the OVCA standard of care regimen of carboplatin plus paclitaxel therapy.
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![MK8033 acts synergistically with carboplatin plus paclitaxel (CarboTaxol or C/T) to inhibit OVCA cell line proliferation. (A) Line graphs show percent OVCA cell viability after 72-h incubation with MK8033, carboplatin plus paclitaxel (carboplatin-to-paclitaxel molar ratio of 20,000:1), and MK8033 plus carboplatin-paclitaxel at constant ratios of 1--2.5:1. Bottom and top horizontal axes indicate MK8033 and carboplatin (in carboplatin-paclitaxel mixture) concentrations, respectively. (B) IC~50~ values of carboplatin-paclitaxel, MK8033 plus carboplatin-paclitaxel, and MK8033 as well as combination index values of synergistic activity in OVCA cell lines. Count (n) refers to the number of replicate experiments.](OR-29-05-2011-g00){#f1-or-29-05-2011}

![MK8033 plus carboplatin-paclitaxel (C/T) response signature may influence overall survival from OVCA. Kaplan-Meier curves depict the association between the expression of the 47-gene MK8033 plus carboplatin-paclitaxel response signature and overall survival from OVCA. Log-rank test P-values indicate significance. Analyses used the publicly available Australian Dataset (Affymetrix U133Plus GeneChips, n=220), with survival information available for 218 of the 220 samples.](OR-29-05-2011-g01){#f2-or-29-05-2011}

###### 

c-Met expression in ovarian cancer samples and available clinical data.

  Sample   Diagnosis                         Score   CR vs. IR   Debulking   Age (years)   Stage   CA125
  -------- --------------------------------- ------- ----------- ----------- ------------- ------- -------
  1        Focal adenocarcinoma              6       CR          O           57            IIIC    541
  2        Papillary serous adenocarcinoma   1       CR          O           84            IIIC    7350
  3        Adenocarcinoma                    2       CR          O           53            IIIC    
  4        Papillary serous adenocarcinoma   4       CR          O           61            IIIC    
  5        Papillary serous adenocarcinoma   6       CR          O           57            IIIC    
  6        Papillary serous adenocarcinoma   1       CR          O           55            IV      
  7        Papillary serous adenocarcinoma   2       CR          O           49            IIIC    305
  8        Papillary serous adenocarcinoma   1       CR          O           65            IIIC    
  9        Papillary serous adenocarcinoma   4       CR          O           60            IIIC    925
  10       Papillary serous adenocarcinoma   2       CR          O           51            IIIB    
  11       Papillary serous adenocarcinoma   4       CR          O           56            IIIC    316
  12       Papillary serous adenocarcinoma   2       CR          O           66            IIIC    224
  13       Papillary serous adenocarcinoma   2       CR          S           56            IIIC    
  14       Papillary serous adenocarcinoma   4       CR          O           73            IIIC    
  15       Papillary serous adenocarcinoma   1       CR          O           62            IIIC    1717
  16       Papillary serous adenocarcinoma   2       CR          O           78            IIIC    
  17       Papillary serous adenocarcinoma   6       CR          O           43            IIIC    64
  18       Papillary serous adenocarcinoma   1       CR          O           45            IIIC    
  19       Papillary serous adenocarcinoma   1       CR          S           74            IIIC    1800
  20       Papillary serous adenocarcinoma   2       CR          O           76            IIIC    
  21       Papillary serous adenocarcinoma   2       IR          S           79            IV      
  22       Papillary serous adenocarcinoma   2       IR          S           71            IV      1636
  23       Papillary serous adenocarcinoma   2       CR          O           56            IIIC    
  24       Papillary serous adenocarcinoma   1       CR          O           81            IIIC    
  25       Papillary serous adenocarcinoma   2       CR          O           56            IIIC    260
  26       papillary serous adenocarcinoma   3       CR          O           35            IV      47
  27       Papillary serous adenocarcinoma   2       CR          O           53            IIIA    
  28       Papillary serous adenocarcinoma   1       CR          S           77            IV      \>600
  29       Papillary serous adenocarcinoma   2       CR          O           65            IIIC    1118
  30       Papillary serous adenocarcinoma   1       CR          S           47            IIIC    712
  31       Papillary serous adenocarcinoma   2       CR          S           76            IIIC    1848
  32       Papillary serous adenocarcinoma   2       CR          O           70            IIIC    
  33       Papillary serous adenocarcinoma   3       CR          S           57            IIIC    266
  34       Adenocarcinoma metastatic         2       CR          O           57            IIIC    175
  35       Papillary serous adenocarcinoma   1       CR          O           65            IV      404
  36       Papillary serous adenocarcinoma   2       CR          O           76            IV      
  37       Papillary serous adenocarcinoma   1       CR          O           66            IIIC    
  38       Papillary serous adenocarcinoma   1       CR          O           68            IIIC    
  39       Papillary serous adenocarcinoma   3       IR          O           73            IIIC    
  40       Papillary serous adenocarcinoma   2       CR          O           63            IV      
  41       Papillary serous adenocarcinoma   2       IR          S           63            IIIC    
  42       Papillary serous adenocarcinoma   2       IR          O           47            IIIC    
  43       Papillary serous adenocarcinoma   2       CR          O           42            IIIC    110
  44       Papillary serous adenocarcinoma   1       CR          O           74            IIIC    4557
  45       Papillary serous adenocarcinoma   2       CR          S           64            IIIC    
  46       Papillary serous adenocarcinoma   2       IR          S           64            IIIC    456
  47       Papillary serous adenocarcinoma   1       IR          O           71            IIIC    
  48       Papillary serous adenocarcinoma   6       IR          O           69            IIIC    
  49       Papillary serous adenocarcinoma   3       CR          O           49            IIIC    
  50       Papillary serous adenocarcinoma   2       CR          O           62            IV      
  51       Papillary serous adenocarcinoma   2       IR                                            
  52       Focal adenocarcinoma              3       CR          S           88            IIIC    
  53       Serous adenocarcinoma             1       IR          O           74            IIIC    101
  54       Papillary serous adenocarcinoma   2       IR          O           71            IIIC    
  55       Papillary serous adenocarcinoma   4       IR          O           69            IIIC    1606
  56       Papillary serous adenocarcinoma   1       IR          O           52            IIIC    
  57       Papillary serous adenocarcinoma   2       CR          O           67            IIIC    
  58       Papillary serous adenocarcinoma   1       CR          O           66            IIIC    824
  59       Papillary Serous adenocarcinoma   2       IR          O           52            IIIC    
  60       Papillary serous adenocarcinoma   1       CR          S           73            IIIC    2354
  61       Papillary serous adenocarcinoma   0       CR          O           75            IIIC    
  62       Papillary serous adenocarcinoma   2       IR          O           65            IIIC    
  63       Focal cellular atypia             n/a     CR          O           74            IIIC    
  64       Papillary serous adenocarcinoma   2       IR          O           79            IIIC    417
  65       Papillary serous adenocarcinoma   1       CR          O           73            IIIC    180
  66       Papillary serous adenocarcinoma   2       IR          O           53            IV      96
  67       Papillary serous adenocarcinoma   1       CR          O           60            IIIC    
  68       Papillary serous adenocarcinoma   2       CR                                            
  69       Papillary serous adenocarcinoma   2       IR          S           53            IIIC    
  70       Papillary serous adenocarcinoma   1       IR          O           41            IIIC    2800
  71       Papillary serous adenocarcinoma   1       CR          O           80            IIIC    
  72       Papillary serous adenocarcinoma   2       CR          O           42            IIIA    
  73       Papillary serous adenocarcinoma   2       IR          S           66            IIIC    90
  74       Papillary serous adenocarcinoma   1       CR          S           60            IIIC    750
  75       Papillary serous adenocarcinoma   4       CR          O           77            IIIC    9814
  76       Papillary serous adenocarcinoma   0       CR          O           72            III     
  77       Papillary serous adenocarcinoma   1       IR          O           66            IIIC    
  78       Papillary serous adenocarcinoma   0       CR          O           54            III     
  79       Papillary serous adenocarcinoma   3       CR          O           38            IIIC    

The c-Met expression score was determined by intensity × cellularity, where intensity was graded as 1, weak; 2, moderate; or 3, strong, and cellularity was graded as 1 when ≤33%, 2 when 34--65%, or 3 when ≥66%. CR, complete response; IR, incomplete response to primary therapy.

###### 

c-Met expression in ovarian cancer cell lines.

  Cell line    Cellularity   Intensity   Score
  ------------ ------------- ----------- -------
  A2008        2             2           4
  A2780CP      0             0           0
  A2780S       1             1           1
  BGI          0             0           0
  C13          3             1           3
  CAOV3        3             1           3
  CHI          0             0           0
  CHI cisR     1             1           1
  CAOV2        3             2           6
  Dov 13       3             2           6
  HeyA8        3             1           3
  IGR-OV1      3             2           6
  IMCC3        2             1           2
  IMCC5        1             1           1
  M41          1             1           1
  M41CSR       2             1           2
  MCAS         3             1           3
  OV2008       1             1           1
  OV90         1             1           1
  Ovary1847    1             1           1
  OVCA 429     2             1           2
  OVCA 432     Acellular     n/a         n/a
  OVCA 433     3             1           3
  OVCA420      1             2           2
  OVCAR10      0             0           0
  OVCAR2       3             2           6
  OVCAR3       2             1           2
  OVCAR4       3             2           6
  OVCAR5       3             2           6
  OVCAR8       3             1           3
  PEO1         3             2           6
  PEO4         2             2           4
  SKOV8        2             1           2
  SKOV3        3             2           6
  SKOV4        0             0           0
  SKOV6        2             1           2
  T8           3             2           6
  Tov-112D     2             1           2
  Tov-21-G     1             1           1
  Tyknu        0             0           0
  Tyknu CisR   0             0           0

The c-Met expression score was determined by intensity × cellularity, where intensity was graded as 1, weak; 2, moderate; or 3, strong, and cellularity was graded as 1 when ≤33%, 2 when 34--65% or 3 when ≥66%.

###### 

Genes associated with ovarian cancer cell sensitivity to MK8033 plus carboplatin-paclitaxel.

  Signature gene symbols                         
  ------------------------ ---------- ---------- -----------
  SETD6                    UBQLN1     HDAC3      LOC653441
  RNF207                   NDOR1      CLTCL1     PHC1
  ABCC8                    IGHM       PPIL4      MATR3
  DNASE1L1                 FBXO4      REST       CLYBL
  ACD                      PRKAA1     LPHN3      MLLT4
  NUP155                   RIPK4      DKFZp667   EFCBP2
  FAM91A2                  TASP1      ACTN2      KIAA0528
  FAM91A1                  ADRBK2     OSBPL6     PPM1J
  MGC5566                  FAM46C     STAR       TMEFF1
  MRPL30                   ITIH4      FUNDC2     SGK269
  MAGIX                    C1orf164   RAB15      LOC389634
  HFE                      IL17RD     EDA        
